Therapeutic update for the management of the hemophilic patient

Hemophilia A and B are hereditary bleeding disorders with a recessive expression linked to the sex chromosome X, affecting mainly male patients in whose cases the clinical expression of the disease depends to a great extent on the levels of the deficient factor. The prevention of hemorrhagic episodes requires actions to maintain adequate hemostasis, achieving a balance between maintaining blood fluidity and restricting the coagulation process to the site of vascular injury. The complexity in the management of these patients constitutes a challenge that currently keeps science searching for new therapeutic options.